Loading
institutionsInstitution
Children's Hospital of Philadelphia
The children's hospital where CAR-T therapy first cured a child's leukaemia (Emily Whitehead, 2012) and where neuroblastoma genomics found ALK.
Also called: CHOP
Overview
Founded in 1855 as the first children's hospital in the United States, CHOP is the paediatric partner of the University of Pennsylvania's Abramson Cancer Center. Stephan Grupp treated Emily Whitehead with CD19 CAR-T cells in 2012 and led the global ELIANA trial that made tisagenlecleucel the first approved CAR-T therapy in 2017. John Maris's group discovered activating ALK mutations in neuroblastoma in 2008, leading Yael Mossé to bring crizotinib and lorlatinib into paediatric trials, and CHOP's Cancer Center runs one of the largest paediatric cancer predisposition and precision medicine programmes. Peter Adamson chaired the Children's Oncology Group from CHOP, and the hospital's cell therapy, proton therapy (through Penn) and neuro-oncology programmes draw referrals internationally.
Location
Philadelphia, PA, US
Type
hospital · University of Pennsylvania
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#154 · 32 points (0 Newsweek + 0 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Children's Hospital of Philadelphia, including child institutions. 571 works · 9,273 citations · 73% open access · 12% clinical trials · 1% reviews.
Oncology works per year
1092022
1232023
1262024
1332025
802026
Most works
- Stephan A. Grupp73 works
- Shannon L. Maude49 works
- Regina M. Myers45 works
- Nirali N. Shah33 works
- Jessica Foster31 works
- Caroline J. Diorio30 works
- Yimei Li28 works
- Joseph A. Fraietta28 works
- Theodore Willis Laetsch28 works
- Richard Aplenc27 works
Most cited
- CAR-T for paediatric leukaemia
- Neuroblastoma genomics and ALK therapy
- Cancer predisposition
- Paediatric proton therapy
John M. Maris
Giulio D'Angio Chair in Neuroblastoma Research, Children's Hospital of Philadelphia
Neuroblastoma genomicsPaediatric oncologyImmunotherapy targets
Neuroblastoma geneticist whose lab found the ALK mutations and immunotherapy targets now in paediatric trials.
Leonard Abramson
U.S. Healthcare founder whose 1997 gift created Penn's Abramson Cancer Center
Cancer centre buildingPaediatric cancer research
In 1997 he and his wife Madlyn, a cancer survivor, gave the University of Pennsylvania the gift that created the Abramson Cancer Center, where CAR-T therapy was later developed.
Madeline Bell
Chief Executive Officer
Paediatric health system leadershipNursingHospital operations
Chief Executive Officer of Children's Hospital of Philadelphia, one of the world's leading paediatric hospitals and a major centre for childhood cancer care and research.
Stephan A. Grupp
Chief, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia; Professor of Pediatrics, University of Pennsylvania
Paediatric CAR T-cell therapyAcute lymphoblastic leukaemiaCytokine release syndrome
Treated the first child with CAR-T cells and led ELIANA, the trial behind the first CAR-T approval.
Stephen P. Hunger
Chief, Division of Oncology, Children's Hospital of Philadelphia; Jeffrey E. Perelman Distinguished Chair in Pediatrics
Paediatric acute lymphoblastic leukaemiaCooperative-group trialsLeukaemia genomics
Chaired the COG leukaemia committee through the era that pushed childhood ALL cure rates above 90%.
Susan Furth
Chief Scientific Officer
Paediatric research leadershipPaediatric nephrologyClinical epidemiology
Paediatric nephrologist and Chief Scientific Officer of Children's Hospital of Philadelphia, overseeing its research institute including paediatric cancer research.
Yael P. Mossé
Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research, Children's Hospital of Philadelphia
NeuroblastomaALK-targeted therapyPaediatric drug development
Discovered ALK mutations in neuroblastoma and led the trials bringing crizotinib and lorlatinib to children.
Carl H. June
Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies
CAR-T cell therapyGene-modified T cellsCellular immunotherapy
Developed the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer.
Similar pages
- Key paperMaude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL
Shares Stephan A. Grupp, Carl H. June, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania.
- PersonEmily Whitehead
Shares Leonard Abramson, Carl H. June, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania.
- Key paperELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL
Shares Stephan A. Grupp, Carl H. June, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania.
- TrialELIANA
Shares Stephan A. Grupp, Tisagenlecleucel, Cytokine release syndrome (CRS), Manufacturing cost and time for living and radioactive medicines.
- TrialCOG ANBL1531
Shares Yael P. Mossé, Lorlatinib, ALK, Children's Oncology Group (COG).
- Key paperJULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma
Shares Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania, Cytokine release syndrome (CRS), Manufacturing cost and time for living and radioactive medicines.
- PersonDavid L. Porter
Shares Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania, CD19, CAR-T cell therapy.
- TrialCOG AALL1731
Shares Stephen P. Hunger, Children's Oncology Group (COG), CD19, Rare and paediatric cancers without markets.
cancers
technologies
targets
drugs
ApprovedSmall-molecule ALK/ROS1/MET TKI (first generation)
Crizotinib · Xalkori
ApprovedSmall-molecule kinase inhibitor (ALK/ROS1)
Lorlatinib · Lorbrena
ApprovedCAR-T (CD19)
Tisagenlecleucel · Kymriah